Faget Quoted on FDA’s Decision to Stop Reviewing COVID-19 Lab Tests
October 7, 2020
BioCentury
Of Counsel Kyle Faget was quoted in a BioCentury article, “FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress,” about the FDA’s announcement that it will no longer review emergency use authorization requests for laboratory developed tests to diagnose COVID-19.
The article cites an Aug. 24 blog post by Faget, who wrote that bringing an LDT to market without securing FDA premarket approval or clearance of, or an emergency use authorization (EUA), comes at a steep cost to clinical laboratories. “Public Health and Emergency Preparedness Act (PREP Act) protection is not available to clinical laboratories opting to use LDTs without FDA premarket review or authorization,” she wrote.
People
Related News
July 28, 2025
In the News
Mark Wolfson Honored in Florida Bar Spotlight
Foley & Lardner LLP partner Mark Wolfson was featured by The Florida Bar for his contributions to the Florida legal community in a "Past Chair Spotlight."
July 24, 2025
In the News
Margaret Nelson Assesses SEC Enforcement Philosophy
Foley & Lardner LLP partner Margaret Gembala Nelson commented in the Private Equity Law Report article, "SEC Enforcement Action Raises Potential Materiality Threshold for Conflicts of Interest," sharing insight on enforcement philosophy at the U.S. Securities and Exchange Commission.
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."